Hebei Medical University Fourth Hospital

This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every th…

This phase 2 trial is testing whether adding an experimental immunotherapy drug (SHR-1701) to standard chemotherapy can improve outcomes for people with a specific type of esophageal cancer (Siewert type II) that can be surgically removed. About 38 participants will receive the d…

This study tests whether a new form of chemotherapy (liposomal irinotecan) combined with other drugs works better than standard irinotecan for people with metastatic colorectal cancer that has progressed after first-line treatment. About 408 adults aged 18 to 75 will be randomly …

This study tests a personalized approach for people with HER2-positive breast cancer. After two cycles of standard therapy, those whose tumors shrink less than 40% will switch to a new drug combination (SHR-A1811 plus pertuzumab) for four more cycles before surgery. The goal is t…

This study tests whether adding a drug called enlonstobart to short-course radiotherapy before surgery can improve outcomes for people with a specific type of advanced rectal cancer (pMMR). About 128 adults will be randomly assigned to receive either the standard treatment or the…

This study tests a new drug called befotertinib combined with radiation therapy for people with advanced non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The goal is to see if this combination can delay cancer growth. About 84 participants …

This phase 2 trial tests the drug olaparib in 30 women with recurrent or metastatic triple-negative breast cancer that has a specific DNA change (BRCA1 promoter methylation) but no BRCA gene mutation. Participants take olaparib pills until the disease worsens or side effects beco…

This phase 2 trial tests whether adding radiotherapy to a combination of two drugs (QL1706 and bevacizumab) can shrink liver tumors that cannot currently be removed by surgery. The goal is to make enough tumors shrink so they can be surgically removed. The study will enroll 60 ad…

This study looks back at medical records of 2000 women with HER2-positive early breast cancer who still had cancer after initial treatment. Researchers want to see which follow-up drug regimen—trastuzumab plus pertuzumab or T-DM1—leads to better long-term outcomes. The goal is to…